GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2020:

• 88,929 shares

• €687 988.75

During the second half of 2020, total trading was:

• On the buy side: 1,525,427 shares for a total amount of €6,221,316.16

• On the sell side: 1,484,196 shares for a total amount of €6,066,211.46

During this same period, the number of trades were:

• On the buy side: 2,623

• On the sell side: 2,638

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

• 27, 911 shares

• €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4™ technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements regarding the objective of its research and development programs. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or “have confidence” or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2019 Universal Registration Document filed with the AMF on 27 May 2020 under n° D.20-0503 and in Section 2 “Risk Factors” of the Company’s Amendment to the Universal Registration Document filed with the AMF on 22 December 2020 under n° D.20-0503-A01, which are available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2019 Annual Report on Form 20-F filed with the SEC on May 27, 2020. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com

PRESS RELATIONS | Media

Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com

APPENDIX
H2 2020

	Buy Side			Sell Side
Date	Number of executions	Number of shares	Traded amounts in EUR	Number of executions	Number of shares	Traded amount in EUR
TOTAL	2 623	1 525 427	6 221 316,16	2 638	1 484 196	6 066 211,46
01/07/2020	8	5001	24 555,04	2	1001	4 905,04
02/07/2020	10	6001	29 254,86	9	6001	29 554,86
03/07/2020	4	3001	14 554,89	5	3001	14 704,89
06/07/2020	8	5001	24 094,90	8	4001	19 454,90
07/07/2020	10	3001	14 354,90	8	4001	19 404,90
08/07/2020	2	1001	4 854,91	5	3001	14 854,91
09/07/2020	14	6001	28 804,92	5	2001	9 604,92
10/07/2020	5	3001	14 104,72	5	3001	14 254,72
13/07/2020	9	4001	18 704,73	4	1001	4 804,73
14/07/2020	12	7001	31 772,69	1	1	4,69
15/07/2020	2	1001	4 504,54	12	6001	27 804,54
16/07/2020	6	3001	13 804,64	6	2001	9 304,64
17/07/2020	3	2001	9 054,60	4	3001	13 804,60
20/07/2020	8	4001	19 304,62	19	10001	48 454,62
21/07/2020	6	3001	15 004,97	6	3001	15 154,97
22/07/2020	9	5001	23 804,93	1	1	4,93
23/07/2020	35	14001	65 957,73	30	18001	85 604,61
24/07/2020	6	5001	23 304,75	7	3001	14 004,75
27/07/2020	6	3001	13 804,70	3	1001	4 604,70
28/07/2020	9	4001	18 054,56	2	1001	4 554,56
29/07/2020	16	8001	34 390,48	6	2001	8 554,48
30/07/2020	12	7001	28 104,18	5	2001	7 954,18
31/07/2020	9	4001	16 853,98	18	9052	37 771,24
03/08/2020	4	1241	5 138,18	8	3241	13 751,14
04/08/2020	7	4001	17 104,34	9	2001	8 754,34
05/08/2020	30	13001	59 404,45	30	18001	82 412,45
06/08/2020	8	4001	17 554,40	7	3001	13 354,40
07/08/2020	6	4001	16 904,36	8	2001	8 454,36
10/08/2020	5	2001	8 454,24	2	1001	4 304,24
11/08/2020	7	5001	22 364,24	19	10001	44 504,24
12/08/2020	11	5001	21 954,38	7	4001	17 754,38
13/08/2020	9	3001	13 154,40	16	5001	22 204,40
14/08/2020	8	4001	17 504,46	1	1	4,46
17/08/2020	4	4001	17 904,38	11	6001	26 764,38
18/08/2020	14	10001	44 504,41	9	8001	36 104,41
19/08/2020	7	4001	17 704,44	9	6001	26 804,44
20/08/2020	6	4001	17 604,49	6	2001	8 904,49
21/08/2020	7	6001	26 704,41	10	8001	35 904,41
24/08/2020	13	6001	26 404,50	5	2001	9 004,50
25/08/2020	8	3001	13 004,39	3	1578	6 943,19
26/08/2020	6	2001	8 604,30	2	1001	4 354,30
27/08/2020	9	3001	12 694,36	2	1001	4 254,32
28/08/2020	17	2001	8 504,26	3	2001	8 604,26
31/08/2020	2	2001	8 504,29	3	2001	8 604,29
01/09/2020	6	3001	12 654,23	3	2001	8 604,23
02/09/2020	4	2001	8 304,18	3	1001	4 204,18
03/09/2020	9	4001	16 304,16	1	1	4,16
04/09/2020	5	2001	8 104,02	5	4001	16 404,02
07/09/2020	1	1	4,08	4	2001	8 304,08
08/09/2020	4	4001	16 304,15	1	1	4,15
09/09/2020	1	1	4,03	1	1	4,03
10/09/2020	9	4001	16 004,00	9	4001	16 204,00
11/09/2020	3	2038	8 335,39	10	4038	16 576,13
14/09/2020	6	5570	22 810,71	7	3533	14 570,02
15/09/2020	10	6001	24 564,16	12	10038	41 461,93
16/09/2020	14	12355	50 000,76	10	6759	27 377,22
17/09/2020	6	4338	17 401,90	5	3092	12 478,54
18/09/2020	15	13764	53 711,81	3	1785	7 122,15
21/09/2020	54	35711	130 617,19	23	23214	85 930,14
22/09/2020	56	37780	128 579,53	37	23425	79 505,48
23/09/2020	10	11053	37 777,14	37	21858	75 243,80
24/09/2020	42	26518	84 804,49	15	10566	33 938,12
25/09/2020	3	1001	3 303,22	71	40193	138 949,64
28/09/2020	42	28001	122 194,04	94	65580	280 622,39
29/09/2020	108	59184	289 427,62	81	44688	222 574,69
30/09/2020	77	46079	223 282,94	69	56966	276 415,17
01/10/2020	156	105679	445 527,89	108	65077	272 012,83
02/10/2020	64	30822	118 216,54	52	33382	129 847,68
05/10/2020	9	3697	14 719,50	11	4222	16 967,97
06/10/2020	1	1	3,98	1	1	3,98
07/10/2020	1	1	3,99	1	1	3,99
08/10/2020	12	6544	25 408,57	7	5158	20 154,63
09/10/2020	10	4761	18 497,21	3	1739	6 821,87
12/10/2020	39	20648	77 097,64	9	7489	27 937,17
13/10/2020	32	20443	72 373,38	18	16209	57 406,80
14/10/2020	12	5294	19 231,27	19	8435	30 823,04
15/10/2020	21	18208	68 856,25	54	30596	116 103,18
16/10/2020	6	5039	19 009,89	3	1279	4 844,91
19/10/2020	1	1	3,75	1	1	3,75
20/10/2020	13	6035	21 826,87	5	3018	11 005,80
21/10/2020	4	1692	5 999,90	4	4018	14 565,70
22/10/2020	16	5188	18 205,33	9	4605	16 316,83
23/10/2020	1	1190	4 176,90	3	2603	9 465,86
26/10/2020	24	13605	46 421,81	1	1	3,50
27/10/2020	42	32038	103 966,86	35	24282	78 944,36
28/10/2020	72	41189	128 615,54	43	44311	140 078,49
29/10/2020	20	11619	36 288,07	7	3454	10 852,04
30/10/2020	20	11623	36 080,25	26	17594	55 071,51
02/11/2020	47	31878	107 111,05	70	41096	137 798,09
03/11/2020	25	20530	69 640,13	36	19350	66 143,53
04/11/2020	27	19404	67 560,68	59	34582	120 337,38
05/11/2020	17	11841	41 744,28	46	19134	68 071,56
06/11/2020	35	19675	67 566,81	19	7002	24 253,56
09/11/2020	35	23518	80 982,51	45	28155	98 055,10
10/11/2020	25	19780	70 120,34	56	25327	89 877,35
11/11/2020	161	82363	354 327,31	245	109412	459 433,58
12/11/2020	56	35001	154 864,28	72	35001	155 314,28
13/11/2020	40	20101	83 015,18	32	18101	75 067,18
16/11/2020	59	30000	122 390,00	57	23863	98 453,67
17/11/2020	22	12001	47 694,11	37	12888	51 705,68
18/11/2020	9	4000	16 299,40	5	4000	16 444,00
19/11/2020	1	1	4,12	1	1	4,12
20/11/2020	4	2001	8 344,12	6	2251	9 401,62
23/11/2020	16	10001	41 074,19	17	9001	37 234,19
24/11/2020	30	13002	54 678,41	35	20001	84 534,13
25/11/2020	32	19000	80 960,12	30	18001	77 242,40
26/11/2020	17	11126	48 980,52	44	19001	84 004,27
27/11/2020	72	35001	172 560,61	71	37001	182 874,70
30/11/2020	44	26876	128 527,54	47	20008	98 479,34
01/12/2020	12	7001	31 714,47	11	7085	32 400,87
02/12/2020	14	8001	35 274,60	16	6002	26 520,70
03/12/2020	29	8953	39 698,47	16	8953	39 913,51
04/12/2020	9	4400	19 754,07	9	4896	22 143,93
07/12/2020	21	10602	47 624,48	21	11702	52 956,30
08/12/2020	28	13299	60 325,22	24	15562	71 181,83
09/12/2020	5	4001	18 496,70	6	4001	18 654,70
10/12/2020	12	6564	29 713,04	8	4601	20 852,65
11/12/2020	94	59167	247 064,47	72	40609	168 101,98
14/12/2020	48	31450	128 194,41	35	26439	108 050,57
15/12/2020	18	11746	47 469,01	19	9827	39 863,39
16/12/2020	18	11191	44 847,24	10	5532	22 431,84
17/12/2020	15	8629	34 338,71	22	18281	73 728,55
18/12/2020	8	5343	21 826,94	4	2672	10 968,95
21/12/2020	14	7007	27 755,33	2	2001	8 064,00
22/12/2020	6	4122	16 825,67	10	5122	20 939,24
23/12/2020	11	6928	27 938,15	7	6928	28 076,69
24/12/2020	9	6106	25 213,23	12	6162	25 604,31
28/12/2020	9	6465	25 871,03	9	5001	20 218,05
29/12/2020	8	4348	17 227,18	16	3869	15 467,69
30/12/2020	1	1	3,96	13	3589	14 473,60
31/12/2020	2	2001	7 988,07	4	1056	4 263,47

Attachment

• GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial